{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:48:10Z","timestamp":1787496490644,"version":"build-2736575974"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2501800"],"award-info":[{"award-number":["2021YFC2501800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071480"],"award-info":[{"award-number":["82071480"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272231"],"award-info":[{"award-number":["82272231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ajp.2024.104193","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:50:12Z","timestamp":1725331812000},"page":"104193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Psychoactive substances for the treatment of neuropsychiatric disorders"],"prefix":"10.1016","volume":"101","author":[{"given":"Zifan","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ajp.2024.104193_bib1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1360-0443.1993.tb02018.x","article-title":"Adverse consequences of lysergic acid diethylamide","volume":"88","author":"Abraham","year":"1993","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/02791072.2019.1581961","article-title":"Beyond LSD: a broader psychedelic zeitgeist during the early to Mid-20(th) century","volume":"51","author":"Aday","year":"2019","journal-title":"J. Psychoact. Drugs"},{"issue":"1601","key":"10.1016\/j.ajp.2024.104193_bib3","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1098\/rstb.2012.0190","article-title":"The neurobiology of depression--revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms","volume":"367","author":"Albert","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1503\/jpn.160175","article-title":"Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism","volume":"42","author":"Aleksandrova","year":"2017","journal-title":"J. Psychiatry Neurosci."},{"issue":"8","key":"10.1016\/j.ajp.2024.104193_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neubiorev.2003.11.012","article-title":"LSD, 5-HT (serotonin), and the evolution of a behavioral assay","volume":"27","author":"Appel","year":"2004","journal-title":"Neurosci. Biobehav Rev."},{"issue":"7354","key":"10.1016\/j.ajp.2024.104193_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"issue":"7578","key":"10.1016\/j.ajp.2024.104193_bib7","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1038\/nature16032","article-title":"Global research challenges and opportunities for mental health and substance-use disorders","volume":"527","author":"Baingana","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ajp.2024.104193_bib8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/archpsyc.1989.01810010025004","article-title":"Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action","volume":"46","author":"Benkelfat","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2024.104193_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu Rev. Med"},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.ajp.2024.104193_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.ajp.2024.104193_bib14","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso","year":"2008","journal-title":"J. Psychoact. Drugs"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/ajp.154.6.805","article-title":"Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers","volume":"154","author":"Breier","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.neuroimage.2009.05.032","article-title":"Generic aspects of complexity in brain imaging data and other biological systems","volume":"47","author":"Bullmore","year":"2009","journal-title":"Neuroimage"},{"issue":"15","key":"10.1016\/j.ajp.2024.104193_bib18","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.ajp.2024.104193_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib20","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Pt 4","key":"10.1016\/j.ajp.2024.104193_bib21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/brain\/awq010","article-title":"The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas","volume":"133","author":"Carhart-Harris","year":"2010","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.ajp.2024.104193_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.biopsych.2013.12.015","article-title":"The Effects of Acutely Administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity","volume":"78","author":"Carhart-Harris","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"10194","key":"10.1016\/j.ajp.2024.104193_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(19)30934-1","article-title":"New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis","volume":"394","author":"Charlson","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/mp.2016.34","article-title":"Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects","volume":"22","author":"Chowdhury","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1515\/RNS.2011.044","article-title":"Structural and synaptic plasticity in stress-related disorders","volume":"22","author":"Christoffel","year":"2011","journal-title":"Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2190\/DCRP-U22M-AUMD-D84H","article-title":"Ecstacy: a review of MDMA and MDA","volume":"16","author":"Climko","year":"1986","journal-title":"Int J. Psychiatry Med"},{"issue":"7","key":"10.1016\/j.ajp.2024.104193_bib27","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1017\/S003329171700263X","article-title":"Diminished medial prefrontal cortex activation during the recollection of stressful events is an acquired characteristic of PTSD","volume":"48","author":"Dahlgren","year":"2018","journal-title":"Psychol. Med"},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"Pt A","key":"10.1016\/j.ajp.2024.104193_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT(1A), D(2) and TAAR(1) receptors","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41386-019-0473-x","article-title":"MDMA enhances pleasantness of affective touch","volume":"45","author":"de Wit","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.ajp.2024.104193_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2174\/1381612822666151214104826","article-title":"Depression, Serotonin and Tryptophan","volume":"22","author":"Dell'Osso","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine Assisted Psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/acs.chemrev.3c00375","article-title":"Serotonin 2A receptor (5-HT(2A)R) agonists: psychedelics and non-hallucinogenic analogues as emerging antidepressants","volume":"124","author":"Duan","year":"2024","journal-title":"Chem. Rev."},{"issue":"6103","key":"10.1016\/j.ajp.2024.104193_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4067\/S0718-48082016000200004","article-title":"Escala de Gravedad de S\u00edntomas Revisada (EGS-R) del Trastorno de Estr\u00e9s Postraum\u00e1tico seg\u00fan el DSM-5: propiedades psicom\u00e9tricas","volume":"34","author":"Echebur\u00faa","year":"2016","journal-title":"Ter. Psicol. \u00d3gica"},{"key":"10.1016\/j.ajp.2024.104193_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibs.2024.02.001","article-title":"TrkB transmembrane domain: bridging structural understanding with therapeutic strategy","author":"Enkavi","year":"2024","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.ajp.2024.104193_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s44220-023-00172-3","article-title":"Exploring mechanisms of psychedelic action using neuroimaging","volume":"2","author":"Erritzoe","year":"2024","journal-title":"Nat. Ment. Health"},{"key":"10.1016\/j.ajp.2024.104193_bib40","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fpsyt.2019.00650","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.ajp.2024.104193_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fphar.2016.00035","article-title":"The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization","volume":"7","author":"Frecska","year":"2016","journal-title":"Front Pharm."},{"issue":"9","key":"10.1016\/j.ajp.2024.104193_bib42","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1360-0443.2006.01511.x","article-title":"The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents","volume":"101","author":"Freudenmann","year":"2006","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pnpbp.2007.07.027","article-title":"Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus","volume":"32","author":"Garcia","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1124\/pr.55.3.3","article-title":"The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \"ecstasy\")","volume":"55","author":"Green","year":"2003","journal-title":"Pharm. Rev."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","article-title":"Subjective reports of the effects of MDMA in a clinical setting","volume":"18","author":"Greer","year":"1986","journal-title":"J. Psychoact. Drugs"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib48","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.euroneuro.2018.03.016","article-title":"Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination","volume":"28","author":"Grimm","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.psychotherapy.1986.40.3.393","article-title":"Can drugs be used to enhance the psychotherapeutic process?","volume":"40","author":"Grinspoon","year":"1986","journal-title":"Am. J. Psychother."},{"issue":"7","key":"10.1016\/j.ajp.2024.104193_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060159","article-title":"Mapping the structural core of human cerebral cortex","volume":"6","author":"Hagmann","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ajp.2024.104193_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2016.01.005","article-title":"Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine","volume":"143","author":"Halberstadt","year":"2016","journal-title":"Pharm. Biochem Behav."},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1615\/CritRevEukaryotGeneExpr.2021038075","article-title":"Novel coronavirus: a review from origin to current status of therapeutic strategies","volume":"31","author":"Hassan","year":"2021","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","article-title":"Therapeutic mechanisms of psychedelics and entactogens","volume":"49","author":"Heifets","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"Pt B","key":"10.1016\/j.ajp.2024.104193_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.expneurol.2016.05.014","article-title":"Noradrenergic dysregulation in the pathophysiology of PTSD","volume":"284","author":"Hendrickson","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ajp.2024.104193_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120302","article-title":"Review of potential psychedelic treatments for PTSD","volume":"439","author":"Henner","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.ajp.2024.104193_bib56","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"Am. J. Psychiatry"},{"issue":"43","key":"10.1016\/j.ajp.2024.104193_bib57","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.ajp.2024.104193_bib58","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek","year":"2014","journal-title":"Soc. Cogn. Affect Neurosci."},{"key":"10.1016\/j.ajp.2024.104193_bib59","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fphar.2018.00330","article-title":"Hypothesis: the psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process","volume":"9","author":"Inserra","year":"2018","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2024.104193_bib61","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neubiorev.2015.08.016","article-title":"The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals","volume":"57","author":"Kamilar-Britt","year":"2015","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.ajp.2024.104193_bib62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1213\/00000539-196405000-00013","article-title":"Study of lysergic acid diethylamide as an analgesic agent","volume":"43","author":"Kast","year":"1964","journal-title":"Anesth. Analg."},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib63","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Curr. Biol."},{"issue":"7","key":"10.1016\/j.ajp.2024.104193_bib64","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med"},{"issue":"13","key":"10.1016\/j.ajp.2024.104193_bib65","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1017\/S0033291717000708","article-title":"Posttraumatic stress disorder in the world mental health surveys","volume":"47","author":"Koenen","year":"2017","journal-title":"Psychol. Med"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib66","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/10783903211033023","article-title":"Ketamine: safe and effective treatment for severe depression","volume":"27","author":"Koss","year":"2021","journal-title":"J. Am. Psychiatr. Nurses Assoc."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jnc.15509","article-title":"From psychiatry to neurology: psychedelics as prospective therapeutics for neurodegenerative disorders","volume":"162","author":"Kozlowska","year":"2022","journal-title":"J. Neurochem"},{"issue":"7","key":"10.1016\/j.ajp.2024.104193_bib68","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the Potential of Psychedelics for the Treatment of PTSD","volume":"23","author":"Krediet","year":"2020","journal-title":"Int J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib70","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nsmb.3014","article-title":"PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome","volume":"22","author":"Kroeze","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib71","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/0269881117699617","article-title":"Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies","volume":"31","author":"Kuypers","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.ajp.2024.104193_bib72","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic Drugs in Biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib73","first-page":"125","article-title":"MDMA to Treat PTSD in Adults","volume":"51","author":"Latimer","year":"2021","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu033","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2014","journal-title":"Int J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib75","first-page":"92","article-title":"Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach","volume":"39","author":"Lerner","year":"2002","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2023.12.004","article-title":"An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions","volume":"47","author":"Lewis","year":"2024","journal-title":"Trends Neurosci."},{"issue":"8","key":"10.1016\/j.ajp.2024.104193_bib77","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/1874473708666150107120522","article-title":"A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects","volume":"7","author":"Liester","year":"2014","journal-title":"Curr. Drug Abus. Rev."},{"issue":"11","key":"10.1016\/j.ajp.2024.104193_bib79","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nat. Ment. Health"},{"issue":"10","key":"10.1016\/j.ajp.2024.104193_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26102948","article-title":"The Therapeutic Potential of Psilocybin","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib81","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41401-023-01201-8","article-title":"Sigma-1 receptor activation mediates the sustained antidepressant effect of ketamine in mice via increasing BDNF levels","volume":"45","author":"Ma","year":"2024","journal-title":"Acta Pharm. Sin."},{"issue":"7984)","key":"10.1016\/j.ajp.2024.104193_bib82","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41586-023-06624-1","article-title":"Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb","volume":"622","author":"Ma","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib83","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/2045125316676092","article-title":"Role of psilocybin in the treatment of depression","volume":"7","author":"Mahapatra","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Maji\u0107","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib85","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/02791072.1998.10399714","article-title":"Treatment of alcoholism using psychedelic drugs: a review of the program of research","volume":"30","author":"Mangini","year":"1998","journal-title":"J. Psychoact. Drugs"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib86","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00213-005-2183-9","article-title":"Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis","volume":"180","author":"Marona-Lewicka","year":"2005","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"10371","key":"10.1016\/j.ajp.2024.104193_bib87","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha","year":"2023","journal-title":"Lancet"},{"issue":"7148","key":"10.1016\/j.ajp.2024.104193_bib88","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature05860","article-title":"Lateral habenula as a source of negative reward signals in dopamine neurons","volume":"447","author":"Matsumoto","year":"2007","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib89","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","article-title":"Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca","volume":"10","author":"McKenna","year":"1984","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib91","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med"},{"issue":"9","key":"10.1016\/j.ajp.2024.104193_bib92","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib93","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib94","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib95","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib96","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study","volume":"27","author":"Mithoefer","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003901","article-title":"The global gap in treatment coverage for major depressive disorder in 84 countries from 2000-2019: a systematic review and Bayesian meta-regression analysis","volume":"19","author":"Moitra","year":"2022","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib98","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"issue":"11","key":"10.1016\/j.ajp.2024.104193_bib99","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib100","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/acps.12818","article-title":"Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations","volume":"136","author":"M\u00fcller","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"issue":"7966","key":"10.1016\/j.ajp.2024.104193_bib101","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","article-title":"Psychedelics reopen the social reward learning critical period","volume":"618","author":"Nardou","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib102","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharm. Rev."},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as Medicines: An Emerging New Paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib104","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1310-3990","article-title":"The History of Psychedelics in Psychiatry","volume":"54","author":"Nichols","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ajp.2024.104193_bib105","article-title":"Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency","volume":"18","author":"Nikkheslat","year":"2021","journal-title":"Brain Behav. Immun. Health"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib106","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2024.104193_bib107","article-title":"Ketamine Toxicity","author":"Orhurhu","year":"2024","journal-title":"StatPearls. StatPearls Publ."},{"issue":"12","key":"10.1016\/j.ajp.2024.104193_bib108","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial","volume":"32","author":"Ot'alora","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib109","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1038\/s41598-024-52967-8","article-title":"Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study","volume":"14","author":"Pagni","year":"2024","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ajp.2024.104193_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/biology12111379","article-title":"Differential cold tolerance on immature stages of geographically divergent ceratitis capitata populations","volume":"12","author":"Papadopoulos","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.ajp.2024.104193_bib111","doi-asserted-by":"crossref","DOI":"10.1177\/2050324518767442","article-title":"The early use of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977\u20131985)","volume":"4","author":"Passie","year":"2018","journal-title":"Drug Sci., Policy Law"},{"key":"10.1016\/j.ajp.2024.104193_bib112","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/164_2018_177","article-title":"Self-experiments with psychoactive substances: a historical perspective","volume":"252","author":"Passie","year":"2018","journal-title":"Handb. Exp. Pharm."},{"issue":"7-8","key":"10.1016\/j.ajp.2024.104193_bib113","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/dta.1377","article-title":"Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence","volume":"4","author":"Passie","year":"2012","journal-title":"Drug Test. Anal."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib114","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0000000000000078","article-title":"N,N-Dimethyltryptamine-Induced Psychosis","volume":"38","author":"Paterson","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib117","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: a convergence of mechanisms","volume":"33","author":"Pittenger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ajp.2024.104193_bib118","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib119","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","article-title":"Psilocybin induces time-dependent changes in global functional connectivity","volume":"88","author":"Preller","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"4717","key":"10.1016\/j.ajp.2024.104193_bib120","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.4023719","article-title":"Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals","volume":"229","author":"Ricaurte","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.ajp.2024.104193_bib121","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.ajp.2024.104193_bib122","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0269881120919957","article-title":"Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis","volume":"34","author":"Romeo","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib123","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross","year":"2018","journal-title":"Int Rev. Psychiatry"},{"issue":"18","key":"10.1016\/j.ajp.2024.104193_bib124","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0163-7258(02)00234-6","article-title":"Therapeutic and adverse actions of serotonin transporter substrates","volume":"95","author":"Rothman","year":"2002","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.ajp.2024.104193_bib126","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02439-2","article-title":"Lasting dynamic effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine ((\u00b1)-DOI) on cognitive flexibility","author":"\u0160abanovi\u0107","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib127","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.neubiorev.2004.08.008","article-title":"Serotonin1B receptors: from protein to physiological function and behavior.","volume":"28","author":"Sari","year":"2004","journal-title":"Neurosci. Biobehav Rev."},{"issue":"5","key":"10.1016\/j.ajp.2024.104193_bib129","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.neuron.2022.12.031","article-title":"The costs and benefits of psychedelics on cognition and mood","volume":"111","author":"Sayal\u0131","year":"2023","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.ajp.2024.104193_bib130","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/0269881114542454","article-title":"Differential effects of MDMA and methylphenidate on social cognition","volume":"28","author":"Schmid","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"16","key":"10.1016\/j.ajp.2024.104193_bib131","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"issue":"26","key":"10.1016\/j.ajp.2024.104193_bib132","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1021\/bi900317a","article-title":"Effect of a single-amino acid substitution of the 43 kDa chlorophyll protein on the oxygen-evolving reaction of the cyanobacterium Synechocystis sp. PCC 6803: analysis of the Glu354Gln mutation","volume":"48","author":"Shimada","year":"2009","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib133","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic Drug Legislative Reform and Legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.ajp.2024.104193_bib134","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","article-title":"MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis","volume":"62","author":"Smith","year":"2022","journal-title":"J. Clin. Pharm."},{"issue":"1-2","key":"10.1016\/j.ajp.2024.104193_bib136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1996","journal-title":"Behav. Brain Res"},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib137","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.ajp.2024.104193_bib138","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41593-023-01436-y","article-title":"GluN2A mediates ketamine-induced rapid antidepressant-like responses","volume":"26","author":"Su","year":"2023","journal-title":"Nat. Neurosci."},{"issue":"61","key":"10.1016\/j.ajp.2024.104193_bib139","doi-asserted-by":"crossref","first-page":"pe12","DOI":"10.1126\/scisignal.261pe12","article-title":"When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor","volume":"2","author":"Su","year":"2009","journal-title":"Sci. Signal"},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib140","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neuron.2007.07.030","article-title":"Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis","volume":"55","author":"Sutton","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.ajp.2024.104193_bib141","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fnins.2016.00423","article-title":"The Endogenous hallucinogen and trace amine N,N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary ipsc-derived cortical neurons and microglia-like immune cells","volume":"10","author":"Szabo","year":"2016","journal-title":"Front Neurosci."},{"issue":"2","key":"10.1016\/j.ajp.2024.104193_bib142","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"Pt 3","key":"10.1016\/j.ajp.2024.104193_bib143","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1113\/jphysiol.2004.071191","article-title":"Alpha 5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro","volume":"559","author":"Towers","year":"2004","journal-title":"J. Physiol."},{"issue":"6633","key":"10.1016\/j.ajp.2024.104193_bib144","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ajp.2024.104193_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199384","article-title":"Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects","volume":"13","author":"Vizeli","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ajp.2024.104193_bib146","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2023.1968","article-title":"Psychedelics as therapeutics-potential and challenges","volume":"80","author":"Volkow","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104193_bib147","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal structure of an LSD-bound human serotonin receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ajp.2024.104193_bib148","unstructured":"WHO, 2022. Mental Health and COVID-19 Early evidence of the pandemic\u2019s impact. World Health Organization."},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib149","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mp.2017.225","article-title":"Engaging homeostatic plasticity to treat depression","volume":"23","author":"Workman","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2024.104193_bib150","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1038\/s41467-023-42780-8","article-title":"Enhanced TARP-\u03b38-PSD-95 coupling in excitatory neurons contributes to the rapid antidepressant-like action of ketamine in male mice","volume":"14","author":"Xue","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ajp.2024.104193_bib151","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.ajp.2024.104193_bib152","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.138","article-title":"3,4-Methylenedioxymethamphetamine facilitates fear extinction learning","volume":"5","author":"Young","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.ajp.2024.104193_bib153","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.ajp.2024.104193_bib154","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201824002867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201824002867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T01:21:49Z","timestamp":1730510509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201824002867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":154,"alternative-id":["S1876201824002867"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104193","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychoactive substances for the treatment of neuropsychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104193"}}